Equities

AxoGen Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

AxoGen Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)33.23
  • Today's Change0.62 / 1.90%
  • Shares traded562.50k
  • 1 Year change+83.19%
  • Beta0.9745
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.

  • Revenue in USD (TTM)214.71m
  • Net income in USD-2.10m
  • Incorporated1977
  • Employees451.00
  • Location
    AxoGen Inc13631 Progress Blvd., Suite 400ALACHUA 32615United StatesUSA
  • Phone+1 (386) 462-6817
  • Fax+1 (386) 462-6801
  • Websitehttps://www.axogeninc.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tandem Diabetes Care Inc1.01bn-203.37m1.28bn2.65k--9.66--1.28-3.05-3.0515.081.961.103.258.64380,000.40-22.20-10.11-30.80-12.3353.2351.67-20.20-11.711.90-9.880.7028--25.7421.0156.86--27.42--
Conmed Corp1.37bn47.06m1.29bn3.90k27.59--10.670.94161.521.5244.24------------------54.0855.563.423.78--3.24----5.189.77-64.4737.66---5.59
Adapthealth Corp3.26bn75.81m1.38bn10.50k18.370.85442.900.42430.55530.555323.9011.940.735417.208.33310,020.301.96-2.812.28-3.1725.3219.632.67-4.190.85842.300.5253--1.9043.84112.19--70.36--
Procept Biorobotics Corp299.91m-84.58m1.55bn756.00--4.08--5.18-1.54-1.545.456.810.67721.813.91396,702.40-19.10-26.94-21.74-29.8164.5554.37-28.20-83.147.20--0.1194--64.84105.2113.68---10.34--
Pulse Biosciences Inc86.00k-74.73m1.56bn75.00--16.82--18,131.77-1.14-1.140.00131.370.0009----1,146.67-74.06-83.75-80.63-94.40-224.42---86,898.84-12,644.5210.01--0.00-------26.95---27.12--
Kestra Medical Technologies Ltd74.26m-138.79m1.57bn330.00--8.44--21.15-2.76-2.761.473.190.4034--9.40225,027.30-71.43-122.23-92.37-192.3546.40---177.06-342.51---116.720.2033--115.05---25.08--150.61--
Quidelortho Corp2.73bn-1.13bn1.60bn6.60k--0.8341--0.5867-16.66-16.6640.2728.270.44782.627.46---18.56-6.45-22.13-7.3946.6753.89-41.45-14.400.90020.67570.5798---1.8910.4444.84------
AtriCure Inc518.31m-28.77m1.62bn1.30k--3.41--3.13-0.608-0.60810.909.590.8291.688.79398,696.20-4.60-3.84-5.24-4.2574.8774.53-5.55-7.132.85-17.960.1252--16.5515.05-46.85--14.00--
Omnicell Inc1.18bn2.05m1.64bn3.60k844.321.3320.011.380.04320.043225.7027.450.57867.195.01--0.10020.73310.13570.976742.4944.800.17321.321.22--0.1198--6.535.84-83.62-42.341.93--
AxoGen Inc214.71m-2.10m1.67bn451.00--12.69343.247.76-0.0486-0.04864.562.621.051.557.75476,073.20-1.03-11.36-1.17-13.0574.7678.42-0.9767-15.372.640.64930.2852--17.8111.9154.12---2.84--
Inspire Medical Systems Inc911.98m145.42m1.71bn1.33k12.022.1910.711.874.974.9730.7527.331.061.188.57684,156.8016.953.0919.003.4885.3984.8315.953.054.56--0.000.0013.6051.21171.77--73.41--
Artivion Inc422.65m-9.12m1.75bn1.60k--3.95126.384.14-0.242-0.2429.489.260.5091.725.16264,153.80-1.10-2.47-1.29-2.6664.5065.02-2.16-5.892.881.290.3324--9.757.0656.37--6.75--
Heartflow Inc-100.00bn-100.00bn1.76bn699.00--6.77----------3.05----------------------------0.00--44.32--22.04------
UFP Technologies Inc597.95m67.12m1.90bn4.15k28.544.6922.063.178.618.6176.7152.370.92614.896.86144,223.8010.4010.1211.8711.5328.5127.0711.2310.641.368.390.26570.0026.0820.5231.2924.4610.82--
Alphatec Holdings Inc728.02m-154.96m1.98bn867.00--173.41--2.73-1.05-1.054.910.23510.94971.287.90839,700.10-20.21-27.43-26.81-34.6969.2366.99-21.29-39.401.24-1.860.941--26.8140.0713.14--48.19--
LeMaitre Vascular Inc240.87m53.34m1.99bn651.0038.415.2531.258.262.282.2810.3516.710.4941.037.45369,993.8010.949.0911.699.8970.9766.2422.1416.6411.45--0.307738.3813.6313.4046.2819.6813.1115.91
Data as of Feb 13 2026. Currency figures normalised to AxoGen Inc's reporting currency: US Dollar USD

Institutional shareholders

44.33%Per cent of shares held by top holders
HolderShares% Held
First Light Asset Management LLCas of 30 Sep 20255.81m11.58%
BlackRock Fund Advisorsas of 31 Dec 20253.27m6.53%
The Vanguard Group, Inc.as of 31 Dec 20252.49m4.97%
Morgan Stanley & Co. LLCas of 31 Dec 20252.43m4.84%
ArrowMark Colorado Holdings LLCas of 30 Sep 20251.96m3.91%
Assenagon Asset Management SA (Germany)as of 31 Dec 20251.38m2.75%
Balyasny Asset Management LPas of 30 Sep 20251.38m2.75%
Soleus Capital Management LP (Investment Management)as of 31 Dec 20251.21m2.41%
Armistice Capital LLCas of 30 Sep 20251.20m2.39%
Geode Capital Management LLCas of 31 Dec 20251.10m2.19%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.